diethyl N-<4-<3-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-5-yl)propyl>benzoyl>-L-glutamate | 125991-54-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: diethyl N-<4-<3-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-5-yl)propyl>benzoyl>-L-glutamate
• 英文别名: N-{4-[3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl}-L-glutamic acid diethyl ester；(S)-diethyl 2-(4-(3-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo-[2,3-d]pyrimidin-5-yl)propyl)benzamido)pentanedioate；Diethyl N-[4{3-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl}benzoyl]-L-glutamate；diethyl N-[4-{3-(2-amino-4-hydroxypyrrolo[2,3-d]-pyrimidin-5-yl)prop-1-yl}benzoyl]-L-glutamate；diethyl (2S)-2-[[4-[3-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]amino]pentanedioate
• CAS: 125991-54-0
• 化学式: C₂₅H₃₁N₅O₆
• 分子量: 497.551
• InChiKey: OITFONLGQMCURT-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  36
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  165
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  diethyl N-<4-<3-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-5-yl)propyl>benzoyl>-L-glutamate 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以68%的产率得到homoLY231514
  参考文献：
  名称：

  一种新型高效合成吡咯并[2,3-d]嘧啶抗癌药：Alimta（LY231514，MTA），均阿利姆他，TNP-351和一些芳基5-取代的吡咯并[2,3-d]嘧啶。

  摘要：

  已经通过一种新方法制备了Alimta以及均Alimta，Alimta的非桥接类似物以及TNP-351，该方法涉及将适当的1-硝基烯烃与2,6-二氨基-3H-嘧啶-4-酮进行迈克尔加成反应。或2,4,6-三氨基嘧啶，然后进行Nef反应，生成伯硝基迈克尔加合物。所得醛与嘧啶6-氨基的自发分子内环化反应产生相应的吡咯并[2,3-d]嘧啶。用相同的方法由上述嘧啶和硝基苯乙烯制备一系列以前未知的5-芳基吡咯并[2，3-d]嘧啶。已经发现，可以通过在含乙酸铵的乙酸中对芳基醛，硝基甲烷和6-氨基嘧啶的混合物进行超声处理而一步制备中间体伯硝基迈克尔加合物。

  DOI：

  10.1021/jo030248h
• 作为产物：
  描述：

  4-(4-羟基-1-丁炔基)苯甲酸甲酯 在 palladium on activated charcoal N-甲基吗啉 、 sodium hydroxide 、 2-氯-4,6-二甲氧基-1,3,5-三嗪 、 氢气 、 sodium acetate 、 甲基磺酰氯 、 三乙胺 、 pyridinium chlorochromate 作用下， 以 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 50.0 ℃ 、344.74 kPa 条件下， 反应 104.5h， 生成 diethyl N-<4-<3-(2-amino-4(3H)-oxo-7H-pyrrolo<2,3-d>pyrimidin-5-yl)propyl>benzoyl>-L-glutamate
  参考文献：
  名称：

  一种新型高效合成吡咯并[2,3-d]嘧啶抗癌药：Alimta（LY231514，MTA），均阿利姆他，TNP-351和一些芳基5-取代的吡咯并[2,3-d]嘧啶。

  摘要：

  已经通过一种新方法制备了Alimta以及均Alimta，Alimta的非桥接类似物以及TNP-351，该方法涉及将适当的1-硝基烯烃与2,6-二氨基-3H-嘧啶-4-酮进行迈克尔加成反应。或2,4,6-三氨基嘧啶，然后进行Nef反应，生成伯硝基迈克尔加合物。所得醛与嘧啶6-氨基的自发分子内环化反应产生相应的吡咯并[2,3-d]嘧啶。用相同的方法由上述嘧啶和硝基苯乙烯制备一系列以前未知的5-芳基吡咯并[2，3-d]嘧啶。已经发现，可以通过在含乙酸铵的乙酸中对芳基醛，硝基甲烷和6-氨基嘧啶的混合物进行超声处理而一步制备中间体伯硝基迈克尔加合物。

  DOI：

  10.1021/jo030248h

文献信息

• Pyrrolopyrimidine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04997838A1

  公开（公告）日：1991-03-05

  A compound of the formula ##STR1## wherein the ring .circle.A is a pyrrole or pyrroline ring, X is an amino group or a hydroxyl group, Y is a hydrogen atom, an amino group or a hydroxyl group, R is a hydrogen atom, a fluorine atom, an alkyl group, an alkenyl group or an alkynyl group, --COOR.sup.1 and --COOR.sup.2 are independently carboxyl groups which may be esterified and n is an integer of 2 to 4, and R may be different in each of the n repeating units, and salts thereof have excellent antitumor effects, and can be used as antitumor agents in mammals.

  一种化合物，其化学式为##STR1##其中环.A是吡咯或吡咯烯环，X是氨基或羟基，Y是氢原子、氨基或羟基，R是氢原子、氟原子、烷基、烯基或炔基，--COOR.sup.1和--COOR.sup.2分别是可以酯化的羧基，n为2到4的整数，且R在n个重复单元中可以各不相同，其盐具有出色的抗肿瘤效果，可用作哺乳动物的抗肿瘤药物。
• [EN] PROCESS FOR THE PREPARATION OF PYRROLO[2,3-D]PYRIMIDINES<br/>[FR] PROCEDE DE PREPARATION DE PYRROLO[2,3-D]PYRIMIDINES
  申请人：UNIV PRINCETON

  公开号：WO2000011004A1

  公开（公告）日：2000-03-02

  4(3H)-X-7H-Pyrrolo[2,3-d]pyrimidines in which X is =O or =NH are prepared by (i) treating a 6-amino-4(3H)-X-pyrimidine with a unsubstituted or substituted 1-nitroalk-1-ene to yield a 6-amino-4(3H)-X-pyrimidine which is substituted in the 5-position by a 1-nitroalk-2-yl group; (ii) converting the 5-(1-nitroalk-2-yl)-6-amino-4(3H)-X-pyrimidine to the corresponding 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyrimidine; and (iii) removing the elements of water from the 5-(1-oxoalk-2-yl)-6-amino-4(3H)-X-pyrimidine to effect cyclization. A typical embodiment involves treating 2,6-diamino-4(3H)-pyrimidone with 1-nitro-4-(4-ethoxycarbonylphenyl)-I-butene to yield 1-nitro-2-(2,6-diamino 4(3H)-oxopyrimidin-5-yl)-4-(4-ethoxycarbonylphenyl)butane which is then treated sequentially with base and acid, without isolation of the intermediate aldehyde, to form 4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoic acid, a valuable known chemical intermediate for the preparation of N-[4-2-(2-hydroxy-4-amino-7H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl}benzoyl]glutamic acid.

  本发明涉及一种制备4(3H)-X-7H-吡咯并[2,3-d]嘧啶的方法，其中X = O或= NH，包括以下步骤：(i)用非取代或取代的1-硝基烯烃处理6-氨基-4(3H)-X-嘧啶，得到在5-位上被1-硝基烷基取代的6-氨基-4(3H)-X-嘧啶；(ii)将5-(1-硝基烷基-2-基)-6-氨基-4(3H)-X-嘧啶转化为相应的5-(1-氧代烷基-2-基)-6-氨基-4(3H)-X-嘧啶；(iii)从5-(1-氧代烷基-2-基)-6-氨基-4(3H)-X-嘧啶中除去水分以进行环化。典型实施例包括用1-硝基-4-(4-乙氧羰基苯基)-1-丁烯处理2,6-二氨基-4(3H)-嘧啶，得到1-硝基-2-(2,6-二氨基4(3H)-氧代嘧啶-5-基)-4-(4-乙氧羰基苯基)丁烷，然后依次用碱和酸处理而不分离中间体醛，形成4-[2-(2-氨基-4(3H)-氧代-7H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酸，这是制备N-[4-2-(2-羟基-4-氨基-7H-吡咯并[2,3-d]-嘧啶-5-基)乙基}苯甲酰]谷氨酸的有价值的已知化学中间体。
• Process for the preparation of pyrrolo[2,3-d]pyrimidines
  申请人：The Trustees of Princeton University

  公开号：US05254687A1

  公开（公告）日：1993-10-19

  5-Substituted pyrrolo[2,3-d]pyrimidines are prepared from a nucleophile of the formula R.sup.2 -C(.dbd.NH)NH.sub.2 and a 2-amino-5-substituted-furan carrying a cyano or carboxy group in the 4-position. A typical example is the preparation of ethyl 4-(2-(2,4-diaminopyrrolo[2,3-d]pyrimidin-5-yl)ethyl}benzoate, an intermediate for the preparation of the known N-[4-2-(2,4-diaminopyrrolo[2,3-d]pyrimidin-5-yl)ethyl}benzoyl]-L-glutamic acid, by allowing guanidine and ethyl 4-[2-(2-amino-3-cyanofur-4-yl)ethyl]benzoate to react under mild conditions.

  5-取代吡咯并[2,3-d]嘧啶是由公式R.sup.2-C(.dbd.NH)NH.sub.2的亲核试剂和一个在4-位带有氰基或羧基的2-氨基-5-取代呋喃制备而成。一个典型的例子是制备乙酸乙酯4-(2-(2,4-二氨基吡咯并[2,3-d]嘧啶-5-基)乙基)苯甲酸酯，这是制备已知的N-[4-2-(2,4-二氨基吡咯并[2,3-d]嘧啶-5-基)乙基}苯甲酰]-L-谷氨酸的中间体，通过在温和条件下让胍和乙酸乙酯4-[2-(2-氨基-3-氰基呋喃-4-基)乙基]苯甲酸酯反应得到。
• Discovery of 5-Substituted Pyrrolo[2,3-<i>d</i>]pyrimidine Antifolates as Dual-Acting Inhibitors of Glycinamide Ribonucleotide Formyltransferase and 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase in De Novo Purine Nucleotide Biosynthesis: Implications of Inhibiting 5-Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase to AMPK Activation and Antitumor Activity
  作者：Shermaine Mitchell-Ryan、Yiqiang Wang、Sudhir Raghavan、Manasa Punaha Ravindra、Eric Hales、Steven Orr、Christina Cherian、Zhanjun Hou、Larry H. Matherly、Aleem Gangjee

  DOI：10.1021/jm401328u

  日期：2013.12.27

  We synthesized 5-substituted pyrrolo[2,3-d]pyrimidine antifolates (compounds 5-10) with one-to-six bridge carbons and a benozyl ring in the side chain as antitumor agents. Compound 8 with a 4-carbon bridge was the most active analogue and potently inhibited proliferation of folate receptor (FR) alpha-expressing Chinese hamster ovary and KB human tumor cells. Growth inhibition was reversed completely or in part by excess folic acid, indicating that FR alpha is involved in cellular uptake, and resulted in S-phase accumulation and apoptosis. Antiproliferative effects of compound 8 toward KB cells were protected by excess adenosine but not thymidine, establishing de novo purine nucleotide biosynthesis as the targeted pathway. However, 5-aminoimidazole-4-carboxamide (AICA) protection was incomplete, suggesting inhibition of both AICA ribonucleotide formyltransferase (AICARFTase) and glycinamide ribonucleotide formyltransferase (GARFTase). Inhibition of GARFTase and AICARFTase by compound 8 was confirmed by cellular metabolic assays and resulted in ATP pool depletion. To our knowledge, this is the first example of an antifolate that acts as a dual inhibitor of GARFTase and AICARFTase as its principal mechanism of action.
• US6066732
  申请人：——

  公开号：——

  公开（公告）日：——